Moderna (MRNA)
(Delayed Data from NSDQ)
$54.10 USD
-0.72 (-1.31%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.12 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$54.10 USD
-0.72 (-1.31%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $54.12 +0.02 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth F Momentum F VGM
Zacks News
Moderna (MRNA) COVID-19 Booster Jab Effective Against Omicron
by Zacks Equity Research
Data from a pseudovirus study demonstrated that the authorized booster dose of Moderna's (MRNA) COVID-19 vaccine significantly increases neutralizing antibody levels against the Omicron variant.
Stock Market News for Dec 21, 2021
by Zacks Equity Research
Benchmarks recorded a steep decline on Monday as investors worried about the fast-spreading omicron variant of COVID-19, raising doubts on the global economic outlook.
Biotech ETFs That Outperformed Last Week
by Sweta Killa
Biotech ETFs was the biggest gainer last week.
Emergent (EBS) Begins Dosing in Study on Influenza Vaccine
by Zacks Equity Research
Emergent (EBS) initiates a phase I study evaluating EBS-UFV-001, the company's investigational universal influenza vaccine candidate.
U.S. CDC Recommends mRNA COVID-19 Vaccines Over J&J's Jab
by Indrajit Bandyopadhyay
The U.S. Centers for Disease Control and Prevention prefers the use of PFE, BNTX and MRNA's mRNA-based COVID-19 vaccines instead of J&J's adenovirus-based vaccine due to higher risks of side effects.
J&J's (JNJ) COVID-19 Booster Jab Gets CHMP Recommendation
by Zacks Equity Research
The CHMP recommends the use of the booster dose of J&J's (JNJ) COVID-19 vaccine in adults in Europe. The booster jab already enjoys authorization in the United States and from the WHO for use in adults.
Biotech Stock Roundup: BMY Increases Dividend, MRNA's Study Results & More
by Zacks Equity Research
Moderna's (MRNA) vaccine study results and other pipeline updates have been the biotech sector???s few key highlights during the past week.
The Zacks Analyst Blog Highlights: Pfizer, BNTX, Moderna, and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BNTX, Moderna, and J&J
Moderna's (MRNA) Flu Vaccine Data Fails to Impress Investors
by Zacks Equity Research
Moderna's (MRNA) early-stage flu vaccine data seems promising but it fails to meet investors' expectations.
Pfizer, BioNTech Booster Gets FDA Nod for 16- & 17-Year Olds
by Zacks Equity Research
FDA authorizes the booster shot of Pfizer (PFE) and BioNTech's (BNTX) COVID-19 vaccine for 16- and 17-year olds.
J&J's (JNJ) COVID-19 Booster Jab Gets WHO Recommendation
by Zacks Equity Research
An advisory group of the World Health Organization recommends the booster dose of J&J's (JNJ) COVID-19 vaccine for use in adults.
Pfizer (PFE) COVID-19 Booster Gives Protection Against Omicron
by Zacks Equity Research
Pfizer (PFE) and BioNTech announce lab test data that demonstrates that the three doses of their COVID-19 vaccine provide significant protection against the Omicron variant.
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
by Zacks Equity Research
Markets Upbeat on Vaccine Efficacy Against Omicron Variant
Remedies for Omicron Apparent, Markets Up Again
by Mark Vickery
New forms of Covid-19 appear to be growing more highly infectious, if not necessarily more life-threatening.
Vaccine Stocks Down as Omicron May Not Be Too Severe
by Kinjel Shah
Stocks of Moderna (MRNA), BioNTech (BNTX), Novavax (NVAX) and Pfizer (PFE) decline as data suggests that Omicron variant may cause less severe cases of COVID-19.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, J&J and Regeneron
5 Defensive ETF Bets as Omicron Enters the United States
by Sweta Jaiswal, FRM
Let's look at some safe ETF plays that investors can consider keeping in mind the rising concerns emanating from the new omicron variant.
Novavax (NVAX) Starts Developing Omicron-Specific COVID Jab
by Zacks Equity Research
Novavax (NVAX) begins evaluating its COVID-19 vaccine against the Omicron variant. The company also starts developing an Omicron-specific COVID-19 vaccine.
COVID-19 Vaccine & Drug Makers Gear Up to Fight Omicron
by Kinjel Shah
The Omicron variant ignites fears that currently available COVID-19 vaccines and treatments could be less effective against it. MRNA, PFE, BNTX, REGN and JNJ are some of the industry players gearing up to fight against this new variant.
Bet on Quality ETFs to Combat Omicron and Fed Worries
by Sweta Jaiswal, FRM
Here we highlight some Quality ETFs that can be promising bets amid the current market conditions.
Top ETF Stories of November
by Sanghamitra Saha
The emergence of the Omicron variant of Covid-19 and inflationary pressure were key highlights of the broader market in November.
Moderna's (MRNA) Stock Falls on Omicron Variant Concerns
by Zacks Equity Research
Moderna (MRNA) shares decline following a two-day rise as the Omicron-variant creates uncertainty with limited data. The next couple of weeks may provide a clearer picture.
Stock Market News for Dec 1, 2021
by Zacks Equity Research
Benchmarks closed sharply lower on Tuesday after Federal Reserve Chairman Jerome Powell proposed US lawmakers consider asset purchases quicker than planned given the present economic scenario.
Sail Through Omicron-Induced Market Volatility With These ETFs
by Sweta Jaiswal, FRM
Low-volatility products could be fascinating picks for those seeking steady investment in equities amid the current market volatility.
Powell Vows to Speed-Up Taper, Market Falls
by Mark Vickery
Shares plummeted for the second trading day in the last three, with the Dow finishing down -652 points, -1.86%, the S&P 500 -1.90% and the Nasdaq dropping -1.55% on the day.